COVID-19 Oxford Vaccine Trial
A chimpanzee adenovirus is modified to make the ChAdOx1 viral vector which is unable to cause disease. Genes coding the spike protein on the surface of the SARS-CoV-2 virus are sequenced and inserted into the ChAdOx1 viral vector to create the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca Vaccine). When the vaccine is given to a person, this allows the cells of their body to express the spike protein and the body produces antibodies against spike proteins. If a person is infected, the immune system attacks the SARS-CoV-2 virus.